202 related articles for article (PubMed ID: 31959628)
1. The discovery and maturation of peptide biologics targeting the small G-protein Cdc42: A bioblockade for Ras-driven signaling.
Tetley GJN; Murphy NP; Bonetto S; Ivanova-Berndt G; Revell J; Mott HR; Cooley RN; Owen D
J Biol Chem; 2020 Feb; 295(9):2866-2884. PubMed ID: 31959628
[TBL] [Abstract][Full Text] [Related]
2. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
Aguilar BJ; Zhou H; Lu Q
Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
[TBL] [Abstract][Full Text] [Related]
3. Cdc42 and k-Ras Control Endothelial Tubulogenesis through Apical Membrane and Cytoskeletal Polarization: Novel Stimulatory Roles for GTPase Effectors, the Small GTPases, Rac2 and Rap1b, and Inhibitory Influence of Arhgap31 and Rasa1.
Norden PR; Kim DJ; Barry DM; Cleaver OB; Davis GE
PLoS One; 2016; 11(1):e0147758. PubMed ID: 26812085
[TBL] [Abstract][Full Text] [Related]
4. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
Guo Y; Kenney SR; Muller CY; Adams S; Rutledge T; Romero E; Murray-Krezan C; Prekeris R; Sklar LA; Hudson LG; Wandinger-Ness A
Mol Cancer Ther; 2015 Oct; 14(10):2215-27. PubMed ID: 26206334
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of small molecule Rac1 inhibitors.
Arnst JL; Hein AL; Taylor MA; Palermo NY; Contreras JI; Sonawane YA; Wahl AO; Ouellette MM; Natarajan A; Yan Y
Oncotarget; 2017 May; 8(21):34586-34600. PubMed ID: 28410221
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.
Trinh TB; Upadhyaya P; Qian Z; Pei D
ACS Comb Sci; 2016 Jan; 18(1):75-85. PubMed ID: 26645887
[TBL] [Abstract][Full Text] [Related]
7. Cdc42: Role in Cancer Management.
Qadir MI; Parveen A; Ali M
Chem Biol Drug Des; 2015 Oct; 86(4):432-9. PubMed ID: 25777055
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.
Upadhyaya P; Qian Z; Selner NG; Clippinger SR; Wu Z; Briesewitz R; Pei D
Angew Chem Int Ed Engl; 2015 Jun; 54(26):7602-6. PubMed ID: 25950772
[TBL] [Abstract][Full Text] [Related]
9. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes.
Teramoto H; Malek RL; Behbahani B; Castellone MD; Lee NH; Gutkind JS
Oncogene; 2003 May; 22(17):2689-97. PubMed ID: 12730683
[TBL] [Abstract][Full Text] [Related]
10. Involvement of IQGAP3, a regulator of Ras/ERK-related cascade, in hepatocyte proliferation in mouse liver regeneration and development.
Kunimoto K; Nojima H; Yamazaki Y; Yoshikawa T; Okanoue T; Tsukita S
J Cell Physiol; 2009 Sep; 220(3):621-31. PubMed ID: 19452445
[TBL] [Abstract][Full Text] [Related]
11. Bond swapping from a charge cloud allows flexible coordination of upstream signals through WASP: Multiple regulatory roles for the WASP basic region.
Tetley GJN; Szeto A; Fountain AJ; Mott HR; Owen D
J Biol Chem; 2018 Sep; 293(39):15136-15151. PubMed ID: 30104412
[TBL] [Abstract][Full Text] [Related]
12. Progress in the therapeutic inhibition of Cdc42 signalling.
Murphy NP; Mott HR; Owen D
Biochem Soc Trans; 2021 Jun; 49(3):1443-1456. PubMed ID: 34100887
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Ral GTPases Using a Stapled Peptide Approach.
Thomas JC; Cooper JM; Clayton NS; Wang C; White MA; Abell C; Owen D; Mott HR
J Biol Chem; 2016 Aug; 291(35):18310-25. PubMed ID: 27334922
[TBL] [Abstract][Full Text] [Related]
14. A bivalent dissectional analysis of the high-affinity interactions between Cdc42 and the Cdc42/Rac interactive binding domains of signaling kinases in Candida albicans.
Su Z; Osborne MJ; Xu P; Xu X; Li Y; Ni F
Biochemistry; 2005 Dec; 44(50):16461-74. PubMed ID: 16342938
[TBL] [Abstract][Full Text] [Related]
15. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
16. Biochemical studies of the mechanism of action of the Cdc42-GTPase-activating protein.
Leonard DA; Lin R; Cerione RA; Manor D
J Biol Chem; 1998 Jun; 273(26):16210-5. PubMed ID: 9632678
[TBL] [Abstract][Full Text] [Related]
17. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.
Oprea TI; Sklar LA; Agola JO; Guo Y; Silberberg M; Roxby J; Vestling A; Romero E; Surviladze Z; Murray-Krezan C; Waller A; Ursu O; Hudson LG; Wandinger-Ness A
PLoS One; 2015; 10(11):e0142182. PubMed ID: 26558612
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.
Aguilar BJ; Zhao Y; Zhou H; Huo S; Chen YH; Lu Q
Cancer Biol Ther; 2019; 20(6):740-749. PubMed ID: 30849276
[TBL] [Abstract][Full Text] [Related]
19. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.
Zuo Y; Wu Y; Chakraborty C
J Cell Physiol; 2012 Apr; 227(4):1399-407. PubMed ID: 21618528
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
Humphries-Bickley T; Castillo-Pichardo L; Hernandez-O'Farrill E; Borrero-Garcia LD; Forestier-Roman I; Gerena Y; Blanco M; Rivera-Robles MJ; Rodriguez-Medina JR; Cubano LA; Vlaar CP; Dharmawardhane S
Mol Cancer Ther; 2017 May; 16(5):805-818. PubMed ID: 28450422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
